CN108524499A - The application of the composition of Thymol, Fipronil and terbinafine HCl, animal dermatosis prevent medication and preparation method thereof - Google Patents
The application of the composition of Thymol, Fipronil and terbinafine HCl, animal dermatosis prevent medication and preparation method thereof Download PDFInfo
- Publication number
- CN108524499A CN108524499A CN201810771312.0A CN201810771312A CN108524499A CN 108524499 A CN108524499 A CN 108524499A CN 201810771312 A CN201810771312 A CN 201810771312A CN 108524499 A CN108524499 A CN 108524499A
- Authority
- CN
- China
- Prior art keywords
- thymol
- fipronil
- animal
- animal dermatosis
- terbinafine hcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Natural products CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 title claims abstract description 116
- 208000017520 skin disease Diseases 0.000 title claims abstract description 87
- 241001465754 Metazoa Species 0.000 title claims abstract description 80
- 206010048768 Dermatosis Diseases 0.000 title claims abstract description 76
- 239000005844 Thymol Substances 0.000 title claims abstract description 60
- 229960000790 thymol Drugs 0.000 title claims abstract description 60
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 239000005899 Fipronil Substances 0.000 title claims abstract description 54
- 229940013764 fipronil Drugs 0.000 title claims abstract description 54
- 229960002722 terbinafine Drugs 0.000 title claims abstract description 51
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 229940079593 drug Drugs 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 125000003639 thymyl group Chemical group C1(=CC(C)=CC=C1C(C)C)* 0.000 title claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 46
- 238000003756 stirring Methods 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 5
- 239000003223 protective agent Substances 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- 239000012752 auxiliary agent Substances 0.000 claims description 11
- 230000035515 penetration Effects 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 238000001228 spectrum Methods 0.000 abstract description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 241000282472 Canis lupus familiaris Species 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 16
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 12
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 210000004209 hair Anatomy 0.000 description 8
- 229960000443 hydrochloric acid Drugs 0.000 description 8
- 229960003639 laurocapram Drugs 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000005639 Lauric acid Substances 0.000 description 6
- 230000000895 acaricidal effect Effects 0.000 description 6
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000003002 pH adjusting agent Substances 0.000 description 6
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 5
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 5
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- 208000001840 Dandruff Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 229940074928 isopropyl myristate Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010029155 Nephropathy toxic Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 241000130764 Tinea Species 0.000 description 3
- 239000000642 acaricide Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000001741 anti-phlogistic effect Effects 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- -1 a- pyrrolidones Chemical compound 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000003646 hair health Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 101100011509 Drosophila melanogaster Baldspot gene Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 206010065954 Stubbornness Diseases 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The application that the invention discloses the compositions of Thymol, Fipronil and terbinafine HCl in animal dermatosis protective agents, animal dermatosis prevention medication and preparation method thereof.The animal dermatosis prevents medication, including Thymol, Fipronil and terbinafine HCl；The animal dermatosis prevention medication preparation method be：Terbinafine HCl, Thymol and Fipronil are added in acceptable auxiliary material, stirring and dissolving, obtain animal dermatosis prevention medication.Animal dermatosis of the present invention prevents composition, can treat to more wide spectrum animal dermatosis and good effect, work fast.
Description
Technical field
The present invention relates to technical field of veterinary, and in particular to Thymol, Fipronil and terbinafine HCl
The application of composition, animal dermatosis prevent medication and preparation method thereof.
Background technology
Pet skin disease is all the problem of pet owners compare headache all the time, and pet skin disease is generally in sweltering heat
Summer and autumn incidence are high, and cold winter incidence is low.For example acarid is mainly in hot summer, so summer is to dote on
Object is most easy to get season of acarid disease.Autumn, The autumn rain fall day after day without ceasing, has excellent environment to the growth of flea, so autumn pet is most
It is susceptible to suffer from skin disease caused by flea.Spring has a humid climate, and pet is most susceptible to suffer from eczema.Skin infection after being ill, pet is because of itching meeting
It ceaselessly tickles with, the case where to cause papule, scurf, pachyderma, hair loss, severe patient causes exanthemv even
Lead to the serious disease of internal medicine etc..
Acarid disease can direct infection, also can be because using the dog cage of illness dog, toy, food basin etc. due tos indirect infection.Acarid kind
Class is more, often endangers the health of pet and owner and medical staff, and acarid disease also has incubation period.The epidemic characteristic of acarid has
There is seasonality and related with the rearing conditions of dog, the kind of dog, age etc..It is sunny when the end of spring and the beginning of summer, the morbidity of acarid disease
Rate is relatively low, survives under conditions of the environment of high humidity low temperature is not suitable in dry and direct sunlight this is because acarid is suitable.
Mostly nosomycosis is infected when dog infects acarid disease simultaneously, this kind of disease is caused by skin resistance declines, extremely obstinate,
And easily repeatedly, it is mainly in summer, Qiu Liangji, moist south is more multiple than the north.The initial stage of mixed infection, skin have scratchiness, because
Tickle and rub disease sites, and to have, bleeding, surface form yellow crust, the different degrees of silvery white of whole body appearance has
The scurf of viscosity, hair is mixed and disorderly, and the withered fracture of hair has slightly in skin, the limb end skin of head, eyes and mouth all around
Flush, the thin layer scales of skin that peel off, erythema shape protuberance.In the morbidity middle and later periods, pars affecta skin thickens, minority will appear round, ellipse and
Irregular sheet hair removal section is simultaneously gradually expanded as plaque-like, has hair root residual and seborrhagia sample oiliness scurf, there is diffusate, shows
For eczema sample.If treatment not in time, can bacterial infection and it is secondary be Pyoderma, there is constitutional symptom, further there is also skin
Stench extract is discharged when extruding, and ultimately succumbs to failure, septicemia or pyemia for skin gauffer, ulcer.
Dog fungus skin disease is mainly drawn by the infection of sporidiole bacteria, trichophyte, candida albicans, sporothrix and chlosma
It rises.In the fungal dermatopathy case of dog, most common cause of disease be Microsporon and trichophyte, wherein microsporum canis about
50%~70% is accounted for, the small spore bacterium of gypsum sample accounts for about 10%~20%, and Trichophyton mentagrophytes account for about 5%~10%.Dog fungus skin disease
Circulation way have direct contact infection, can also be passed by using mediate contacts such as the infection bath towel of dog, dog cage, food basin, underbeds
It broadcasts, and can be posted more than sample quantity in dog and pass through air borne under intensive environment.Dog fungus skin disease have it is apparent it is seasonal,
The course of disease is long, Chang Fanfu stubbornnesses are broken out, and the defective dog of juvenile dogs, immunity degradation and skin having a delicate constitution is easy to be infected,
In the seasonal prevalence of low temperature and high relative humidity.The fungal dermatopathy of dog had both seriously affected the beauty of dog and had influenced their normal instructions
White silk and daily life, also bring certain threat to the health of pet owner.Because dog grows climatic environment difference, kind year
Age is different, inhabitation feeding conditions are different, and the type of Dog fungus skin disease also has difference.Dog fungus skin disease not only refractory treatment
And it easily recurs.Fungal dermatopathy at the initial stage of a disease, generally occurs within that erythema, local hair are mixed and disorderly, hair is withered breaks to form
Circular bald spot, infection epidermis with a little thin layer scales of skin that peel off.It falls ill the later stage, extreme itch, hair removal section extends around, lesion
Position is rounded, oval and irregular, and is gradually expanded as the dryness or oiliness of plaque-like, residual hair root and seborrhagia sample
Scurf is formed circular " tinea ", therefore is commonly called as depilation tinea, tinea glabrosa, and with the skin injury of large area, hair follicle seriously destroys, more sternly
Severe one face and four limbs form crust and suppurate, and have exudation around warts, with hyperkeratinization or ulcer.Dog Fungal Skin
Disease is clinically more typical, accounts for about canine dermopathic 16.86%.
Invention content
Based on this, it is necessary to provide the compositions of a kind of Thymol, Fipronil and terbinafine HCl to exist by the present invention
Application in animal dermatosis protective agents, the drug can treat to more wide spectrum animal dermatosis and good effect, speed of action
Soon.
The present invention, which there is a need to, provides a kind of animal dermatosis prevention medication.
The present invention also provides the preparation methods that a kind of animal dermatosis prevents medication.
In order to achieve the object of the present invention, the present invention uses following technical scheme：
A kind of composition answering in animal dermatosis protective agents of Thymol, Fipronil and terbinafine HCl
With.
Above-mentioned animal dermatosis protective agents, Fipronil have in terms of preventing the flea with pet, mite and louse
There is wide spectrum, efficient, terbinafine HCl is not likely to produce drug resistance, liver to deep fungal infection function well, small toxicity
Renal damage is small, and Thymol not only has very strong acaricidal action, also has the biologies such as bactericidal antiphlogistic, anti-oxidant, anti-corrosion, eliminating the phlegm
Activity, safe, toxicity is low, is easily obtained, and since it is with phenols smell, is also commonly used for acaricide and fragrance, three's group
Conjunction forms said medicine, cooperates, synergistic effect, can broader spectrum for the treatment of pet skin it is sick, and good effect, speed of action
Soon.
In some of embodiments, the mass ratio of the Thymol and the Fipronil is (0.001-30)：(1-
40)。
In some of embodiments, the mass ratio of the Thymol and the terbinafine HCl is (0.001-30)：
(0.1-30)。
The present invention also provides a kind of animal dermatosis to prevent medication, including Thymol, Fipronil and hydrochloric acid spy compare naphthalene
It is fragrant.
Above-mentioned animal dermatosis prevents medication, has in terms of flea, mite and louse of the Fipronil with prevention pet
There is wide spectrum, efficient, terbinafine HCl is not likely to produce drug resistance, liver to deep fungal infection function well, small toxicity
Renal damage is small, and Thymol not only has very strong acaricidal action, also has the biologies such as bactericidal antiphlogistic, anti-oxidant, anti-corrosion, eliminating the phlegm
Activity, safe, toxicity is low, is easily obtained, and since it is with phenols smell, is also commonly used for acaricide and fragrance, three's group
Conjunction forms said medicine, cooperates, synergistic effect, can broader spectrum for the treatment of pet skin it is sick, and good effect, speed of action
Soon.
In some of embodiments, the mass ratio of the Thymol and the Fipronil is (0.001-30)：(1-
40)。
In some of embodiments, the mass ratio of the Thymol and the terbinafine HCl is (0.001-30)：
(0.1-30)。
In some of embodiments, the animal dermatosis prevention medication is drops or dashing agent.
In some of embodiments, the animal dermatosis prevents medication, includes the component of following parts by weight：Thyme
Phenol 0.001%-30%, Fipronil 1%-40%, terbinafine HCl 0.1%-30%, appropriate auxiliary agent and balance of solvent.
In some of embodiments, the auxiliary agent includes pH adjusting agent, preservative, antioxidant, surfactant, transdermal
One or more of bleeding agent.
The present invention also adopts the following technical scheme that：A kind of preparation method of animal dermatosis prevention medication, including walk as follows
Suddenly：
The terbinafine HCl, Thymol and Fipronil are added in acceptable auxiliary material, stirring and dissolving obtains
Animal dermatosis prevents medication.
Specific implementation mode
It to facilitate the understanding of the present invention, below will be to invention is more fully described.But the present invention can be to be permitted
Mostly different form is realized, however it is not limited to embodiment described herein.Make on the contrary, purpose of providing these embodiments is
It is more thorough and comprehensive to the understanding of the disclosure.
Unless otherwise defined, all of technologies and scientific terms used here by the article and belong to the technical field of the present invention
The normally understood meaning of technical staff is identical.Used term is intended merely to description tool in the description of the invention herein
The purpose of the embodiment of body, it is not intended that in the limitation present invention.
The composition that the present invention provides a kind of Thymol, Fipronil and terbinafine HCl is prevented in animal dermatosis
Application in drug.
Preferably, Thymol and the mass ratio of Fipronil are (0.001-30)：(1-40).Thymol is special with hydrochloric acid
Mass ratio than naphthalene sweet smell is (0.001-30)：(0.1-30).
The present invention also provides a kind of animal dermatosis to prevent medication, including Thymol, Fipronil and hydrochloric acid spy compare naphthalene
It is fragrant.Preferably, Thymol and the mass ratio of Fipronil are (0.001-30)：(1-40).Thymol compares naphthalene with hydrochloric acid spy
Fragrant mass ratio is (0.001-30)：(0.1-30).
Above-mentioned animal dermatosis prevention medication is drops or dashing agent.
Preferably drops is made in the present invention.
For example, animal dermatosis prevents medication drops, include the component of following parts by weight：Thymol 0.001%-
30%, Fipronil 1%-40%, terbinafine HCl 0.1%-30%, appropriate auxiliary agent and balance of solvent.
Closer, animal dermatosis prevents medication drops, includes the component of following parts by weight：Thymol
0.01%-20%, Fipronil 1%-30%, terbinafine HCl 0.1%-20%, appropriate auxiliary agent and balance of solvent.
Such as Thymol 0.001%, 0.01%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25% and
30%；Fipronil 1,3%, 5%, 7%, 10%, 12%, 13%, 15%, 20%, 25%, 30%, 35%, 38% and
40%；Terbinafine HCl 0.1%, 0.2%, 3%, 5%, 7%, 10%, 12%, 13%, 15%, 20%, 22%, 25% and
30%.
Above-mentioned animal dermatosis prevents medication, has in terms of flea, mite and louse of the Fipronil with prevention pet
There is wide spectrum, efficient, terbinafine HCl is not likely to produce drug resistance, liver to deep fungal infection function well, small toxicity
Renal damage is small, and Thymol not only has very strong acaricidal action, also has the biologies such as bactericidal antiphlogistic, anti-oxidant, anti-corrosion, eliminating the phlegm
Activity, safe, toxicity is low, is easily obtained, and since it is with phenols smell, is also commonly used for acaricide and fragrance, three's group
Conjunction forms said medicine, cooperates, synergistic effect, being capable of broader spectrum for the treatment of pet skin disease.
Solvent includes Laurocapram, glycerine, propylene glycol, a- pyrrolidones, dimethyl sulfoxide (DMSO), dimethylformamide, two
One or more of methylacetamide, polyethylene glycol, benzyl carbinol, ethyl alcohol, water and tea oil.
Auxiliary agent includes one or more of pH adjusting agent, antioxidant, transdermal penetration agent.
The acid-base value that pH adjusting agent therein is used to adjust drug is close or consistent with the acid-base scale of skin of pet.PH tune
The content for saving agent is 0.01%-5%, is adjusted according to the type of specific medication.PH adjusting agent includes citric acid, hydrochloric acid, phosphorus
One or more of acid, benzoic acid, sodium hydroxide and potassium hydroxide.Such as the content of pH adjusting agent be 0.01%, 0.1%,
0.5%, 1%, 2%, 3%, 4% and 5%.
The content of antioxidant is 0.01%-5%, which can prevent or delay to aoxidize, and improve the stabilization of drug
Property.The antioxidant includes one kind in tocopherol, butylated hydroxy anisole, dibutyl hydroxy toluene and tert-butyl hydroquinone
Or it is several.Such as the content of antioxidant be 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%,
2%, 3%, 4% and 5%.
Transdermal penetration agent be propylene glycol, Laurocapram, Miglyol 812N and diethylene glycol monoethyl ether wherein
One or more.Propylene glycol can both make solvent, can also do transdermal penetration agent, and very used in effect in pharmaceutical preparation
It is good, therefore transdermal penetration agent is preferably propylene glycol.The content of transdermal penetration agent is 0.1%-5%, such as transdermal penetration agent contains
Amount is 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 2%, 3%, 4% and 5%.
When said medicine is dashing agent, auxiliary material includes one kind or several in solvent, transdermal agent, cosolvent and antioxidant
Kind.
The method for preparing above-mentioned animal dermatosis prevention medication, includes the following steps：By terbinafine HCl, Thymol
And Fipronil is added in acceptable auxiliary material, stirring and dissolving, obtains animal dermatosis prevention medication.
For example, when above-mentioned animal dermatosis prevention medication is drops, preparation method is as follows：
S1, partial solvent is added to the container；
S2, it is separately added into terbinafine HCl, Thymol, Fipronil and auxiliary agent stirring and dissolving in a reservoir；
S3, residual solvent is added to the container, is stirred evenly, obtain animal dermatosis prevention composition.
When solvent is a variety of, before step S1, also there is step S01：Multi-solvents are mixed, stirring is equal
It is even.
After step s 3, also there is step S4：Animal dermatosis prevention composition is fitted into drop bottle.
When needing that the auxiliary agents such as pH adjusting agent, antioxidant, transdermal penetration agent are added, terbinafine HCl, hundred are being added
In after fragrant phenol, Fipronil dissolving, add auxiliary agent dissolving or auxiliary agent and terbinafine HCl, Thymol, Fipronil
It is added to the container and is dissolved together.
For example, when being prepared into dashing agent, by terbinafine HCl, Thymol, Fipronil, solvent, transdermal agent and resist
Oxidant is added in solvent one by one, and all dissolvings are completed to obtain the final product.
The embodiment that will be further illustrated the present invention below by several embodiments：
Embodiment one
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is drops, is grouped as by the group of following parts by weight：
Thymol 0.5%, Fipronil 5%, terbinafine HCl 1% and propylene glycol surplus.
The animal dermatosis prevention composition preparation method be：50% propylene glycol is added to the container, in a reservoir
It is separately added into terbinafine HCl, Thymol, Fipronil, stirring and dissolving；Remaining propylene glycol is added to the container, is stirred
Uniformly, animal dermatosis prevention composition is obtained, which is fitted into drop bottle.
Embodiment two
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is drops, is grouped as by the group of following parts by weight：
Thymol 0.5%, Fipronil 5%, terbinafine HCl 1%, butylated hydroxy anisole 0.1% and propylene glycol surplus.
The animal dermatosis prevention composition preparation method be：60% propylene glycol is added to the container, in a reservoir
It is separately added into terbinafine HCl, Thymol, Fipronil and butylated hydroxy anisole, stirring and dissolving；By remaining the third two
Alcohol is added to the container, and is stirred evenly, and obtains animal dermatosis prevention composition, which is fitted into drop bottle.
Embodiment three
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is drops, is grouped as by the group of following parts by weight：
Thymol 0.01%, Fipronil 30%, terbinafine HCl 20%, dibutyl hydroxy toluene 0.1%, Laurocapram
2% and polyethylene glycol surplus.
The animal dermatosis prevention composition preparation method be：40% polyethylene glycol is added to the container, in container
In be separately added into terbinafine HCl, Thymol, Fipronil, dibutyl hydroxy toluene and Laurocapram, stirring and dissolving；
Remaining polyethylene glycol is added to the container, is stirred evenly, animal dermatosis prevention composition is obtained, which is packed into drop bottle
In.
Example IV
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is drops, is grouped as by the group of following parts by weight：
Thymol 0.01%, Fipronil 40%, terbinafine HCl 0.1%, hydrochloric acid 0.01%, Laurocapram 1% and ethyl alcohol
Surplus.
The animal dermatosis prevention composition preparation method be：30% ethyl alcohol is added to the container, is divided in a reservoir
Not Jia Ru terbinafine HCl, Thymol, Fipronil, hydrochloric acid and Laurocapram, stirring and dissolving；Remaining ethyl alcohol is added
Enter in container, stir evenly, obtains animal dermatosis prevention composition, which is fitted into drop bottle.
Embodiment five
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is drops, is grouped as by the group of following parts by weight：
Thymol 10%, Fipronil 1%, terbinafine HCl 30%, dimethyl sulfoxide (DMSO) 5%, lauric acid Azone 5%, butyl
Hydroxyanisole 0.5% and ethanol balance.
The animal dermatosis prevention composition preparation method be：30% ethyl alcohol is added to the container, is divided in a reservoir
Not Jia Ru terbinafine HCl, Thymol, Fipronil, dimethyl sulfoxide (DMSO), Laurocapram and butylated hydroxy anisole, stir
Mix dissolving；Remaining ethyl alcohol is added to the container, is stirred evenly, animal dermatosis prevention composition is obtained, which is packed into and is dripped
In bottle.
Embodiment six
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is drops, is grouped as by the group of following parts by weight：
Thymol 15%, Fipronil 5%, terbinafine HCl 5%, isopropyl myristate 10%, lauric acid Azone 20%,
Isopropanol 20% and ethanol balance.
The animal dermatosis prevention composition preparation method be：Whole ethyl alcohol is added to the container, is divided in a reservoir
Not Jia Ru terbinafine HCl, Thymol, Fipronil, isopropyl myristate and Laurocapram, stirring and dissolving；It will be different
Propyl alcohol is added to the container, and is stirred evenly, and obtains animal dermatosis prevention composition, which is fitted into drop bottle.
Embodiment seven
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is dashing agent, is grouped by the group of following parts by weight
At：Thymol 20%, Fipronil 1%, terbinafine HCl 30%, dimethyl sulfoxide (DMSO) 5%, lauric acid Azone 5%, fourth
Base hydroxyanisole 0.5% and ethanol balance.
The animal dermatosis prevention composition preparation method be：By Thymol, Fipronil, terbinafine HCl,
Dimethyl sulfoxide (DMSO), lauric acid Azone and butylated hydroxy anisole sequentially add in ethyl alcohol, after previous component stirring and dissolving again
Add next component, after stirring and dissolving is complete to obtain the final product.
Embodiment eight
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is dashing agent, is grouped by the group of following parts by weight
At：Thymol 30%, Fipronil 5%, terbinafine HCl 5%, isopropyl myristate 10%, lauric acid Azone
20%, isopropanol 20% and ethanol balance.
The animal dermatosis prevention composition preparation method be：Ethyl alcohol and isopropanol are mixed into solvent, then will
Thymol, Fei Poluo, hydrochloric acid spy sequentially add than naphthalene, isopropyl myristate and lauric acid Azone in solvent, wait for previous
Add next component after component stirring and dissolving again, after stirring and dissolving is complete to obtain the final product.
Comparative example one
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is drops, is grouped as by the group of following parts by weight：
Fipronil 5%, terbinafine HCl 1% and propylene glycol surplus.
The animal dermatosis prevention composition preparation method be：50% propylene glycol is added to the container, in a reservoir
It is separately added into terbinafine HCl and Fipronil, stirring and dissolving；Remaining propylene glycol is added to the container, is stirred evenly, so
The medicine is fitted into drop bottle afterwards.
Comparative example two
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is drops, is grouped as by the group of following parts by weight：
Thymol 0.5%, Fipronil 5% and propylene glycol surplus.
The animal dermatosis prevention composition preparation method be：50% propylene glycol is added to the container, in a reservoir
It is separately added into Thymol and Fipronil, stirring and dissolving；Remaining propylene glycol is added to the container, is stirred evenly, then will
The medicine is fitted into drop bottle.
Comparative example three
The present invention provides a kind of animal dermatosis prevention composition, and dosage form is drops, is grouped as by the group of following parts by weight：
Thymol, terbinafine HCl 1% and propylene glycol surplus.
The animal dermatosis prevention composition preparation method be：50% propylene glycol is added to the container, in a reservoir
It is separately added into Thymol and terbinafine HCl, stirring and dissolving；Remaining propylene glycol is added to the container, is stirred evenly, so
The medicine is fitted into drop bottle afterwards.
Comparative example four：
Animal dermatosis described in the comparative example prevents composition, and dosage form is drops comprising the component of following parts by weight：
Thymol 0.5% and propylene glycol surplus.
The animal dermatosis prevention composition preparation method be：Thymol is added in propylene glycol, stirring and dissolving, so
The medicine is fitted into drop bottle afterwards.
Comparative example five：
Animal dermatosis described in the comparative example prevents composition, and dosage form is drops comprising the component of following parts by weight：
Fipronil 5% and propylene glycol surplus.
The animal dermatosis prevention composition preparation method be：Fipronil is added in propylene glycol, stirring and dissolving, so
The medicine is fitted into drop bottle afterwards.
Comparative example six：
Animal dermatosis described in the comparative example prevents composition, and dosage form is drops comprising the component of following parts by weight：
Terbinafine HCl 1% and propylene glycol surplus.
The animal dermatosis prevention composition preparation method be：Terbinafine HCl is added in propylene glycol, stirring is molten
The medicine, is then fitted into drop bottle by solution.
Above-described embodiment one will be proved to embodiment six and comparative example for animal or pet skin according to experiment below
The control effect of disease.
With 30 days for test period, percutaneously use dog above-described embodiment one to the drug of embodiment six and comparative example, it will
78 infected dogs of skin are randomly divided into 13 groups every group 6.Every dog receives a Local treatment, first group to the 6th group difference
For corresponding embodiment one to embodiment six, the 7th group to the 12nd group corresponds to comparative example one to comparative example six respectively, control group not into
Row processing.It is administered using delivery device test tube, 0.1ml is administered in per kilogram of body weight.
After treatment, dog was observed at the 1st, 2,3,7,11,15,20,25,30 day, and whether there is or not scratching, friction symptom, skin healths
Situation and hair health count cure rate, the results are shown in Table one.
Table one
The drug described in embodiment one to embodiment six is can be seen that from above-mentioned experiment, the 1st, 2,3,7,11,15,20,
Observe within 25,30 days that the skin of animal, hair health are superior to comparative example one to comparative example five, and control group is not administered
, cure rate is far below embodiment and comparative example, illustrates that drug of the present invention is high to animal dermatosis cure rate, effect speed
Degree is fast.
Several embodiments of the invention above described embodiment only expresses, the description thereof is more specific and detailed, but simultaneously
Cannot the limitation to the scope of the claims of the present invention therefore be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to the guarantor of the present invention
Protect range.Therefore, the protection domain of patent of the present invention should be determined by the appended claims.
Claims (10)
1. a kind of composition of Thymol, Fipronil and terbinafine HCl answering in animal dermatosis protective agents
With.
2. application according to claim 1, which is characterized in that the Thymol and the mass ratio of the Fipronil are
(0.001-30)：(1-40).
3. application according to claim 1 or 2, which is characterized in that the Thymol and the terbinafine HCl
Mass ratio is (0.001-30)：(0.1-30).
4. a kind of animal dermatosis prevents medication, which is characterized in that including Thymol, Fipronil and terbinafine HCl.
5. animal dermatosis according to claim 4 prevents medication, which is characterized in that the Thymol non-is sprinkled with described
The mass ratio of Buddhist nun sieve is (0.001-30)：(1-40).
6. animal dermatosis according to claim 4 or 5 prevents medication, which is characterized in that the Thymol with it is described
The mass ratio of terbinafine HCl is (0.001-30)：(0.1-30).
7. animal dermatosis according to claim 4 prevents medication, which is characterized in that the animal dermatosis prevents medication
For drops or dashing agent.
8. animal dermatosis according to claim 4 or 5 prevents medication, which is characterized in that include the group of following parts by weight
Point：Thymol 0.001%-30%, Fipronil 1%-40%, terbinafine HCl 0.1%-30%, appropriate auxiliary agent and molten
Agent surplus.
9. animal dermatosis according to claim 8 prevents composition, which is characterized in that the auxiliary agent includes that pH is adjusted
One or more of agent, preservative, antioxidant, surfactant, transdermal penetration agent.
10. a kind of preparation method of the animal dermatosis prevention medication prepared described in claim 4-9, which is characterized in that including
Following steps：
Terbinafine HCl, Thymol and Fipronil are added in acceptable auxiliary material, stirring and dissolving obtains animal skin
Disease prevention medication.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810771312.0A CN108524499A (en) | 2018-07-13 | 2018-07-13 | The application of the composition of Thymol, Fipronil and terbinafine HCl, animal dermatosis prevent medication and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810771312.0A CN108524499A (en) | 2018-07-13 | 2018-07-13 | The application of the composition of Thymol, Fipronil and terbinafine HCl, animal dermatosis prevent medication and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108524499A true CN108524499A (en) | 2018-09-14 |
Family
ID=63488099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810771312.0A Pending CN108524499A (en) | 2018-07-13 | 2018-07-13 | The application of the composition of Thymol, Fipronil and terbinafine HCl, animal dermatosis prevent medication and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108524499A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112263571A (en) * | 2020-10-27 | 2021-01-26 | 青岛大学附属医院 | Application of thymol in preparation of medicine for treating fungal keratitis |
| CN112426373A (en) * | 2020-11-27 | 2021-03-02 | 佛山市南海东方澳龙制药有限公司 | Pet shampoo with functions of treating ectoparasite dermatosis and resisting bacteria and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008048963A2 (en) * | 2006-10-16 | 2008-04-24 | Sergeant's Pet Care Products Inc. | Natural compositions for killing parasites on a companion animal |
| CN102065851A (en) * | 2008-04-25 | 2011-05-18 | 纳米生物公司 | Nanoemulsions for treating fungal, yeast and mold infections |
| CN105012960A (en) * | 2014-04-16 | 2015-11-04 | 上海现代药物制剂工程研究中心有限公司 | Film-forming gel composition, application and wound protecting material |
| CN105688168A (en) * | 2016-03-19 | 2016-06-22 | 上海申亚动物保健品阜阳有限公司 | Pet all-in-one insect expelling spray and preparation method thereof |
| US20170225958A1 (en) * | 2014-08-01 | 2017-08-10 | Smart Inovation, Lda | Functional particles, production process and uses |
-
2018
- 2018-07-13 CN CN201810771312.0A patent/CN108524499A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008048963A2 (en) * | 2006-10-16 | 2008-04-24 | Sergeant's Pet Care Products Inc. | Natural compositions for killing parasites on a companion animal |
| CN102065851A (en) * | 2008-04-25 | 2011-05-18 | 纳米生物公司 | Nanoemulsions for treating fungal, yeast and mold infections |
| CN105012960A (en) * | 2014-04-16 | 2015-11-04 | 上海现代药物制剂工程研究中心有限公司 | Film-forming gel composition, application and wound protecting material |
| US20170225958A1 (en) * | 2014-08-01 | 2017-08-10 | Smart Inovation, Lda | Functional particles, production process and uses |
| CN105688168A (en) * | 2016-03-19 | 2016-06-22 | 上海申亚动物保健品阜阳有限公司 | Pet all-in-one insect expelling spray and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 闭兴明等: "麝香草酚体外抗真菌活性研究", 《中国农学通报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112263571A (en) * | 2020-10-27 | 2021-01-26 | 青岛大学附属医院 | Application of thymol in preparation of medicine for treating fungal keratitis |
| CN112426373A (en) * | 2020-11-27 | 2021-03-02 | 佛山市南海东方澳龙制药有限公司 | Pet shampoo with functions of treating ectoparasite dermatosis and resisting bacteria and preparation method thereof |
| CN112426373B (en) * | 2020-11-27 | 2021-07-27 | 佛山市南海东方澳龙制药有限公司 | Pet shampoo with functions of treating ectoparasite dermatosis and resisting bacteria and preparation method thereof |
| WO2022110487A1 (en) * | 2020-11-27 | 2022-06-02 | 佛山市南海东方澳龙制药有限公司 | Pet shampoo with functions of treating ectoparasite skin diseases and resisting microbia and preparation method therefor |
| JP2022551208A (en) * | 2020-11-27 | 2022-12-08 | 佛山市南海東方澳龍製薬有限公司 | Shampoo for pets with functions of treating skin diseases caused by ectoparasites and antibacterial, and manufacturing method |
| JP7271014B2 (en) | 2020-11-27 | 2023-05-11 | 佛山市南海東方澳龍製薬有限公司 | Shampoo for pets with functions of treating skin diseases caused by ectoparasites and antibacterial, and manufacturing method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100506036C (en) | A composition for preservation of corpse specimens and its preparation method | |
| RU2408372C2 (en) | Application of octenidine dihydrochloride in semisolid preparations | |
| CN101856029A (en) | Pesticide combination containing etoxazole and abamectin | |
| CN102274286B (en) | Cinnamomum longepaniculatum leaf volatile oil inclusion complex and preparation method thereof | |
| CN108524499A (en) | The application of the composition of Thymol, Fipronil and terbinafine HCl, animal dermatosis prevent medication and preparation method thereof | |
| CN112972379B (en) | Gamitmycin emulsion, preparation method and application thereof in prevention and treatment of porcine ileitis | |
| CN107258839A (en) | A kind of composite disinfectant and preparation method thereof | |
| CN101474284B (en) | External use medicament for treating fungal dermatopathy | |
| KR102154252B1 (en) | Composition for Antimicrobial and Antifungal Comprising Baicalein and Wogonin as Active Ingredient | |
| KR20120120376A (en) | Topical antiparasitic formulations | |
| US20090209604A1 (en) | Topical combination therapy for treating acne | |
| CN118236450A (en) | A compound plant essential oil for inhibiting pathogenic fungi and preparation method thereof | |
| CN104430466A (en) | Water emulsion composition for preventing and treating rice sheath blight and preparation method thereof | |
| CN101869109A (en) | Germicide containing zincpolyanemine and kresoxim-methyl | |
| CN104430467A (en) | Pesticide composition containing acetamiprid and application of composition | |
| CN101632359B (en) | Sterilization combination for preventing and curing pear scab and aqueous emulsion thereof and preparation method thereof | |
| CN108739824A (en) | Prevent bactericidal composition and its application of mulberry tree foxiness disease | |
| KR20190042164A (en) | Composition and method for non-atiseptic wet tissues containing the ingredient to inhibit microbial propagation | |
| CN114514929A (en) | Disinfectant, and preparation method and application thereof | |
| CN106070255A (en) | A kind of novel pesticide preventing and treating bacterial diseases of plants and preparation method thereof | |
| CN105211114A (en) | A kind of plant pesticide composition containing matrine and eucalyptus oil | |
| WO2020138773A1 (en) | Stable liquid composition for preserving cosmetics, containing pca ethyl cocoyl arginate | |
| CN112972437B (en) | Long-acting external preparation containing iodonitrophenol and preparation method and application thereof | |
| CN103734141A (en) | Compound pesticide suspension agent containing isoprothiolane and hexaconazole | |
| CN111568886B (en) | A kind of Chinese and Western medicine compound film coating agent for treating cattle mite disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180914 |
|
| RJ01 | Rejection of invention patent application after publication |